Full-Time

Senior Director

Technical Operations

Updated on 8/21/2026

Tarsus Pharmaceuticals

Tarsus Pharmaceuticals

201-500 employees

Develops FDA-approved ophthalmic therapies

Compensation Overview

$255k - $357k/yr

+ Bonus + Stock equity

Irvine, CA, USA

Hybrid

Hybrid work environment; remote work may be available for the right candidate.

Bachelor's, Master's, PhD

Category
Biology & Biotech (1)
Required Skills
Supply Chain Management
Risk Management

Get referred to Tarsus Pharmaceuticals

See people who can refer or advise you

Requirements
  • A Bachelor of Science, Master of Science, or Ph.D. in a relevant engineering or science field.
  • At least 15 years of progressively responsible experience in technical operations and/or manufacturing support in pharmaceutical manufacturing; doctorate holders require at least 10 years of total experience.
  • A strong understanding of technical and scientific challenges related to production processes used to manufacture sterile products and package those products.
  • Strong understanding of project management systems and tools, along with strong business and financial skills.
  • An established track record of people management, problem solving, collaboration, leadership, and communication.
  • Strategic leadership ability to translate corporate vision and strategy into departmental goals and objectives, adjust plans and tactics to changing priorities, and use market data.
  • Strong communication and change management skills, with the ability to build relationships vertically and horizontally.
  • The ability to escalate difficult issues and make tough decisions.
  • The ability to work in a fast-paced environment and demonstrate a learning orientation.
Responsibilities
  • Provide strategic leadership and oversight of drug product manufacturing and external contract development and manufacturing organization operations from late-stage development through commercialization.
  • Define and lead end-to-end drug product manufacturing strategy from late-phase clinical through commercial stages, ensuring scalability of processes, supply chain, and the contract manufacturing organization network.
  • Manage operational complexity across programs, manufacturing sites, and partnerships.
  • Provide senior oversight of contract development and manufacturing organization relationships, including performance management, capacity planning, and long-term partnership strategy.
  • Establish governance models and develop external-partner relationships that ensure accountability, transparency, and execution.
  • Lead the selection, onboarding, and strategic management of contract manufacturing organizations for development and commercial supply.
  • Lead resolution of critical manufacturing issues, including deviations, investigations, and high-risk events, and serve as the escalation point for complex technical and operational challenges.
  • Develop and implement proactive risk-mitigation strategies to ensure continuity of supply.
  • Partner cross-functionally with Pharmaceutical Sciences, Analytical Development, Supply Chain, Regulatory, and Quality to align chemistry, manufacturing, and controls strategy and execution.
  • Integrate development, manufacturing, capacity planning, and supply planning activities and influence cross-functional decision-making at the program and organizational levels.
  • Lead multiple chemistry, manufacturing, and controls programs, ensuring alignment with regulatory, technical, and corporate strategy.
  • Oversee manufacturing execution at contract manufacturing organizations, including batch strategy, documentation, and compliance.
  • Ensure readiness and contribution to chemistry, manufacturing, and controls regulatory submissions and inspections.
  • Establish clear ownership and accountability for manufacturing strategy and execution and enable reliable, scalable supply for clinical and commercial programs.
  • Reduce operational risk through proactive issue management and decision-making and support the organization’s transition to commercial-stage operations.
  • Manage Person-in-Plant coverage for manufacturing activities.
  • Develop and manage the budget for chemistry, manufacturing, and controls programs and collaborate with Finance to address budget variance.
Desired Qualifications
  • Experience with sterile ophthalmic dosage forms, solid oral dose and packaging, and topical dermal formulations.
Tarsus Pharmaceuticals

Tarsus Pharmaceuticals

View

Tarsus Pharmaceuticals develops and markets treatments for eye care and infectious diseases, including XDEMVY, an FDA-approved lotilaner eye drop for Demodex Blepharitis. It works by applying the ophthalmic solution to the eyelids to kill Demodex mites and reduce eyelid inflammation. The company differentiates itself with a focused ocular and infectious diseases portfolio and by pursuing collaborations to advance its pipeline alongside selling approved products. Its goal is to address unmet medical needs, grow its product lineup, and expand into additional indications in eye care and infectious diseases.

Company Size

201-500

Company Stage

IPO

Headquarters

Irvine, California

Founded

2017

Get referred to Tarsus Pharmaceuticals

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 XDEMVY sales hit $173.9 million, up 69%, lifting guidance to $705 million.
  • Cash reached $449.7 million on June 30, 2026, funding Alkeus integration and trials.
  • Alkeus adds Phase 3 Stargardt disease, expanding Tarsus beyond XDEMVY dependence.

What critics are saying

  • Culper Research accused Tarsus on July 1, 2026 of an illegal Medicare copay scheme.
  • Glaukos entered Demodex blepharitis in June 2026, threatening XDEMVY pricing and share gains.
  • Any DOJ action on XDEMVY copay practices can cripple Tarsus's only revenue engine.

What makes Tarsus Pharmaceuticals unique

  • XDEMVY remains the only FDA-approved treatment for Demodex blepharitis, preserving first-mover advantage.
  • Tarsus now combines commercial ophthalmology with late-stage retina assets from iRenix and Alkeus.
  • Its lotilaner platform already delivered a $15 million China milestone on March 23, 2026.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Paid Vacation

Hybrid Work Options

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-2%

2 year growth

3%
Yahoo Finance
Aug 7th, 2026
Tarsus raises 2026 XDEMVY sales outlook to $705M, acquires Alkeus for $450M upfront

Tarsus Pharmaceuticals reported strong Q2 performance for its Demodex blepharitis treatment XDEMVY, with sales rising 69% year-over-year to $173.9 million. The company raised its 2026 sales guidance to $685–$705 million, noting that over 700,000 patients have used the treatment since launch. Tarsus announced plans to acquire Alkeus Pharmaceuticals for $450 million upfront, adding late-stage Stargardt disease therapy ALK-001 to its pipeline. The Phase III NORTHSTAR trial is underway, with top-line results expected in the second half of 2029. The acquisition will expand Tarsus' strategy beyond XDEMVY into retina care. However, the company raised 2026 R&D guidance to $190–$210 million due to increased near-term spending. Profitability could potentially arrive in 2027, subject to acquisition-related costs.

Vision Monday
Aug 7th, 2026
Tarsus to acquire Alkeus in $450 million deal, reports strong Quarter and half.

Tarsus to acquire Alkeus in $450 million deal, reports strong Quarter and half. Friday, August 7, 2026 12:24 AM IRVINE, Calif. - Tarsus Pharmaceuticals announced yesterday that it has entered into a definitive agreement to acquire Alkeus Pharmaceuticals, Inc., a privately held retinal disease-focused biotechnology company developing gildeuretinol (ALK-001), an investigational once-daily oral therapy for Stargardt disease. The deal includes an upfront consideration of about $450 million, the companies said, comprising $270 million in cash and $180 million in Tarsus common stock. The pending transaction is expected to close this year, and also includes a milestone of up to $350 million upon potential regulatory approval and first commercial sale. The news was announced along with a strong unaudited financial report that saw total Q2 revenue for Tarsus rise to $173.9 million and first half revenue rise to nearly $336 million. According to the announcement, the planned acquisition of Alkeus represents what Tarsus said is an important step in its long-term strategy to build a leading eyecare company by bringing differentiated medicines to patients with significant unmet needs. The acquisition is expected to expand Tarsus' growing presence in retina, complement the capabilities established through the acquisition of iRenix Medical last month, and add a differentiated phase 3 program potentially addressing Stargardt disease. "From the beginning, our strategy has been to build a leading eyecare company by identifying significant diseases where patients have been starving for innovation and bringing forward medicines with the potential to change the standard of care," said Bobby Azamian, MD, Ph.D., CEO and chairman of Tarsus. "We believe gildeuretinol has the potential to be a transformational medicine for Stargardt disease and complements the retina capabilities we are already building through IRX-101. We also have tremendous respect for the Alkeus team and the exceptional work they have done to identify and bring forward an optimal asset to potentially address this blinding disease." Second Quarter and First Half Reporting The acquisition announcement came nearly concurrent with strong unaudited second quarter and first half reporting from Tarsus. Net sales of $173.9 million marked more than 69 percent growth versus last year's Q2 of $102.7 million, with net product sales of XDEMVY (lotilaner ophthalmic solution) 0.25%, a prescription eye drop designed to treat Demodex blepharitis, serving as a primary revenue driver, as well as what the company said was higher volume and improvements in the gross-to-net discount. Total first-half revenue for the company was reported at nearly $336 million (versus $181 million for the same period last year), with $319.3 million attributed to XDEMVY product sales and $16.7 million attributed to license fees and collaborations. Cost of sales in Q2 were $12.1 million compared with $6.2 million for the same period in 2025, due to manufacturing costs related to Xdemvy, the company said. Research and development expenses totaled $31.0 million compared with $15.6 million for the same period in 2025. Selling, general and administrative expenses were $150.7 million compared with $103.0 million for the same period in 2025. Net loss in the second quarter narrowed to $18.6 million, compared with $20.3 million for the same period in 2025, the company said. As of June 30, 2026, cash, cash equivalents and marketable securities were $449.7 million. The company also took the further step of increasing 2026 net sales guidance for XDEMVY to $685 million to $705 million. Related to the pending acquisition, Barclays is acting as exclusive financial advisor to Tarsus and Jefferies is acting as exclusive financial advisor to Alkeus. Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP is acting as legal counsel to Tarsus, and Latham & Watkins LLP is acting as legal counsel to Alkeus.

Central Charts
Aug 6th, 2026
Tarsus Pharmaceuticals raises $125M in oversubscribed PIPE financing to fund Alkeus acquisition

Tarsus Pharmaceuticals has secured $125 million through an oversubscribed private placement equity financing. The transaction includes participation from investors in Alkeus Pharmaceuticals, which Tarsus announced it would acquire earlier the same day. Notable investors include TCGX, Bain Capital Life Sciences, Wellington Management, ADAR1 Capital Management, Sirenia Capital Management LP, RTW Investments, and Vestal Point Capital. The company is selling 2,098,519 shares of common stock at $56 per share and pre-funded warrants to purchase 133,625 additional shares. The financing is expected to close on 7 August 2026. Tarsus intends to use the proceeds to fund clinical development, commercial activities, and general corporate purposes. Barclays is serving as lead placement agent, with BofA Securities and William Blair as co-placement agents.

GlobeNewswire
Aug 6th, 2026
Tarsus Pharmaceuticals acquires Alkeus for $450M to advance Stargardt disease treatment

Tarsus Pharmaceuticals has agreed to acquire Alkeus Pharmaceuticals for approximately $450 million upfront, consisting of $270 million in cash and $180 million in Tarsus stock. The deal includes potential milestone payments of up to $350 million upon regulatory approval and first commercial sale, plus low single-digit royalties. The acquisition adds gildeuretinol (ALK-001), a Phase 3 oral investigational medicine for Stargardt disease, an inherited retinal condition affecting over 36,000 people in the US with no FDA-approved treatments. More than 400 individuals have been treated with the drug to date, showing encouraging clinical findings. Top-line Phase 3 NORTHSTAR data are expected in the second half of 2029. The transaction has been approved by both companies' boards and Alkeus stockholders. It is expected to close in 2026, subject to regulatory clearances and customary conditions.

Minichart
Jul 9th, 2026
Tarsus Pharmaceuticals Acquires iRenix Medical to Advance Eye Care with Late-Stage IRX-101 Asset

Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) has announced a major strategic acquisition, taking over privately held iRenix Medical, Inc., a clinical-stage ophthalmic biopharmaceutical company. This transaction marks a significant step in Tarsus’ ambition to expand its leadership in the eye care market and could have material implications for the company’s future growth, pipeline development, and share price.